International Flavors (IFF) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

International Flavors (IFF) reported Q3 results with revenue of $2.69 billion, a 7.9% year-over-year decline, yet exceeding the consensus estimate of $2.63 billion by 2.57%. Earnings per share (EPS) increased to $1.05 from $1.04 a year ago, also surpassing the $1.02 estimate by 2.94%. While overall revenue declined, most key segment net sales and Adjusted Operating EBITDA figures, including Health & Biosciences and Scent, outperformed analyst expectations, indicating underlying operational strength despite top-line pressures. The company's stock has underperformed the S&P 500 over the past month and currently holds a Zacks Rank #3 (Hold).

Analysis

International Flavors (IFF) reported Q3 2025 revenue of $2.69 billion, marking a 7.9% year-over-year decline, yet it surpassed the Zacks Consensus Estimate of $2.63 billion by 2.57%. Concurrently, EPS rose to $1.05 from $1.04 a year ago, exceeding the $1.02 consensus estimate by 2.94%, indicating effective cost management or higher-margin sales mix despite top-line pressures.

Despite the overall revenue contraction, most key segment net sales and Adjusted Operating EBITDA figures outperformed analyst expectations. Notably, Net Sales for Health & Biosciences increased by 1.2% year-over-year to $577 million, beating estimates, and Scent net sales grew 6.4% year-over-year to $652 million, also exceeding forecasts. Adjusted Operating EBITDA for Health & Biosciences, Scent, and Taste segments also surpassed average analyst estimates, suggesting underlying operational strength in these divisions.

However, the stock's recent market performance has lagged, with a +0.9% return over the past month compared to the S&P 500's +2.1% change. The current Zacks Rank #3 (Hold) further suggests that IFF is expected to perform in line with the broader market in the near term, reflecting a neutral outlook despite the positive earnings and segment-level surprises. The Food Ingredients segment's Adjusted Operating EBITDA of $106 million missed its $109.32 million estimate.

This mixed performance, characterized by headline revenue decline but strong operational beats in key segments and positive EPS surprise, points to a company navigating a challenging revenue environment while demonstrating efficiency and targeted growth in specific areas.

Key Decisions for Investors

• Investors should closely monitor future revenue trends for IFF, particularly the year-over-year growth trajectory, to assess the sustainability of its operational improvements.
• Evaluate the continued outperformance of the Health & Biosciences and Scent segments as potential drivers for future growth amidst broader market challenges.
• Consider the stock's recent underperformance relative to the S&P 500 and its Zacks Rank #3 (Hold) when making near-term portfolio allocation decisions, balancing the positive earnings surprise against macro headwinds.